Cytotechnology

, Volume 19, Issue 3, pp 191–197

Relationship of LRP-human major vault protein toin vitro and clinical resistance to anticancer drugs

  • Miguel A. Izquierdo
  • George L. Scheffer
  • Marcel J. Flens
  • Robert H. Shoemaker
  • Leonard H. Rome
  • Rik J. Scheper
Article

Abstract

Multidrug resistance (MDR) has been related to two members of the ABC-superfamily of transporters, P-glycoprotein (Pgp) and Multidrug Resistance-associated Protein (MRP). We have described a 110 kD protein termed the Lung Resistance-related Protein (LRP) that is overexpressed in several non-Pgp MDR cell lines of different histogenetic origin. Reversal of MDR parallels a decrease in LRP expression. In a panel of 61 cancer cell lines which have not been subjected to laboratory drug selection, LRP was a superior predictor forin vitro resistance to MDR-related drugs when compared to Pgp and MRP, and LRP's predictive value extended to MDR unrelated drugs, such as platinum compounds. LRP is widely distributed in clinical cancer specimens, but the frequency of LRP expression inversely correlates with the known chemosensitivity of different tumour types. Furthermore, LRP expression at diagnosis has been shown to be a strong and independent prognostic factor for response to chemotherapy and outcome in acute myeloid leukemia and ovarian carcinoma (platinum-based treatment) patients. Recently, LRP has been identified as the human major protein. Vaults are novel cellular organelles broadly distributed and highly conserved among diverse eukaryotic cells, suggesting that they play a role in fundamental cell processes. Vaults localise to nuclear pore complexes and may be the central plug of the nuclear pore complexes. Vaults structure and localisation support a transport function for this particle which could involve a variety of substrates. Vaults may therefore play a role in drug resistance by regulating the nucleocytoplasmic transport of drugs.

Key words

drug resistance lung resistance-related protein multidrug resistance multidrug resistance-associated protein P-glycoprotein vaults 

Abbreviations

LRP

Lung Resistance-related Protein

MVP

Major Vault Protein

MDR

Multidrug resistance

MRP

Multidrug resistance-associated Protein

NPC

Nuclear Pore Complex

Pgp

P-glycoprotein

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Childs S and Ling V (1994) The MDR superfamily of genes and its biological implications. In: De Vita, VT Helleman S, Rosenberg SA (eds.). Important Advances in Oncology, pp 21–36. Philadelphia: JB Lippincott Company.Google Scholar
  2. Chugani DC, Rome LH and Kedersha NL (1993) Evidence that vault ribonucleoprotein particles localise to the nuclear pore complex. J Cell Sci 106: 23–29.Google Scholar
  3. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJLM, Scheper RJ and Zaman GJR (1994) Immunochemical detection of MRP in human multidrug-resistant tumour cells by monoclonal antibodies. Cancer res 54: 4457–4563.Google Scholar
  4. Flens MJ, Zaman GJR, Van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, Van der Groep P, De Haas M, Meijer CJLM, Scheper RJ (1996) Tissue distribution of the multidrug resistance-associated protein (MRP), Am J Pathol (in press).Google Scholar
  5. Futscher BW, Abbaszadegan MR, Domann F and Dalton WS (1994) Analysis of MRP mRNA in mitoxantrone selected multidrug-resistant human tumor cells. Biochem. Pharmacol 47: 1601–1604.Google Scholar
  6. Gervasoni JE, Fields SZ, Krishna S, Baker MA, Rosado M, Thuraisamy K, Hindenburg AA and Taub RN (1991) Subcellular distribution of daunorubicin in P-glycoprotein-positive and-negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res 51: 4955–4963.Google Scholar
  7. Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR and Scheper RJ (1955a) Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. Int J Cancer (in press).Google Scholar
  8. Izquierdo MA, van der Zee A, Vermorken JB, van der Valk P, Belein JAM, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, de Vries EGE and Scheper RJ (1995b) Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarion carcinoma. J Natl Cancer Inst 87: 1230–1237.Google Scholar
  9. Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJLM, Van der Valk P and Scheper RJ (1996) Broad distribution of the multidrug resistance-related vault protein LRP in normal human tissues and tumors. Am J Pathol (in press).Google Scholar
  10. Kedersha NL and Rome LH (1986) Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol 103: 699–709.Google Scholar
  11. Kedersha NL, Miquel MC, Bittner D and Rome LH (1990) Vaults II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. J. Cell Biol 110: 895–901.Google Scholar
  12. Kedersha NL, Heuser JE, Chugani DC and Rome LH (1991) Vaults III. Vault ribonucleoprotein particles open into flower-like structures which octagonal symmetry. J Cell Biol 112: 225–235.Google Scholar
  13. Kickhoefer VA and Rome LH (1994) The sequence of a cDNA encoding the major vault protein fromRattus norvegicus. Gene 151: 257–260.Google Scholar
  14. Klumper E, de Boer ML, Pieters R, Huismans DR, Rottier MMA, Zwaan MC, Scheffer GL, Scheper RJ and Veerman AJP (1995) Non-P-glycoprotein mediated resistance to anthracylines is associated with the expression of a 110 kD protein in relapsed childhood acute lymphoblastic leukemia. In: Klumper E (ed). drug resistance and relapsed leukemia (Thesis), pp 117–130. VU University Pess.Google Scholar
  15. Kuiper CM, Broxterman HJ, Baas F, Schuurhuis GJ, Hausma HJ, Scheffer GL, Lankelma J and Pinedo HHM (1990) Drug transport variants without P-glucoprotein over-expression from a human aquamous-lung-cancer cell line after selection with doxorubicin. J Cell Pharmacol 1: 35–41.Google Scholar
  16. List A, Spier CS, Abbaszadegan M, Grogan TM, Gree JP, Wolff SN, Scheper RJ and Dalton WS (1993) Non-P-glycoprotein (PGP) mediated multidrug resistance (MDR): Identification of a novel drug resistance phenotype with prognostic relevance in acute myeloid leukemia (AML). Blood 82: 443a (abst. 1755).Google Scholar
  17. Rome L, Kedersha N and Chugani D (1991) Unlocking vaults: organelles in search of a function. Trends Cell Biol 1: 47–50.Google Scholar
  18. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC and Scheper RJ (1995) The drug-resistance related protein LRP is the human major vault protein. Nature Med 1: 578–582.Google Scholar
  19. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen THM, van Kalken CK, Slovak ML, de Vries EGE, van der Valk P, Meijer CJLM and Oinedo HM (1993) Overexpression of a 110 kD vesicular protein in non-P-glycoprotein mediated multidrug-resistance. Cancer Res 53: 1475–1479.Google Scholar
  20. Schadendorf D, Makki A, Stahr C, van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, and Czarnetzki BM (1995) Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 147: 1545–1552.Google Scholar
  21. Schuurhuis GJ, Broxterman HJ, de Lange JHM, Pinedo HM, van Heijningen TH, Kuiper CM, Scheffer GL, Scheper RJ, van Kalken CK, Baak and Lankelma J (1991) Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer 64: 857–861.Google Scholar
  22. Shao Y, de Giuli R, Wyler B and Lehnert M (1995) Overexpression of MDR1/P-glycoprotein and MRP but not LRP is mutually exclusive in multidrug resistant human myeloma cells selected with doxorubicin. Proc Am Ass Cancer Res 36: 337 (abst. 2006).Google Scholar
  23. Slovak ML, Peley Ho J, Cole SPC, Deeley RG, de Vries EGE, Broxterman HJ, Scheffer GL and Scheper RJ (1995) The LRF gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: Evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res. 55: 4214–4219.Google Scholar
  24. Vasu SK, Kedersha NL and Rome LH (1993), cDNA cloning and disruption of the major vault protein alpha gene (mvpA) inDictyostelium discoideum. J Biol Chem 268: 15356–15360.Google Scholar
  25. Versantvoort CHM, Withoff S, Boxterman HJ, Scheper RJ, Mulder NH and de Vries EGE (1995) Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer 61: 375–380.Google Scholar
  26. Zaman GJR, Flens MJ, van Leusden MR, de Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ and Borst P (1994). The human multidrug resistance-associated protein (MRP) is a plasma membrane drug efflux pump. Proc Natl Acad Sci 91: 8822–8826.Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Miguel A. Izquierdo
    • 1
  • George L. Scheffer
    • 1
  • Marcel J. Flens
    • 1
  • Robert H. Shoemaker
    • 2
  • Leonard H. Rome
    • 3
  • Rik J. Scheper
    • 1
  1. 1.Department of PathologyFree University HospitalAmsterdamThe Netherlands
  2. 2.Laboratory of Drug Discovery Research and Development, Developmental Therapeutic Program, Division of Cancer TreatmentNational Cancer InstituteFrederickUSA
  3. 3.Department of Biological ChemistryUniversity of California School of MedicineLos AngelesUSA

Personalised recommendations